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Biocompatibility issues with modern implants in bone. A Review
for clinical orthopaedics
Abstract
Skeletal defects may result from traumatic, infectious, congenital or neoplastic processes and are
considered to be a challenge for reconstructive surgery. Although the autologous bone graft is still the
“gold standard”, there is continuing demand for bone substitutes because of associated disadvantages,
such as limited supply and potential donor side morbidity [1]. This is not only true for indications in
orthopedic and craniomaxillofacial surgeries, but also in repairing endodontic defects and in dental
implantology.
Before clinical use all new bone substitute materials have to be validated for their osseoconductive and -
depending on the composition of the material also -inductive ability, as well as for their long-term
biocompatibility in bone. Serving this purpose various bone healing models to test osteocompatibility
and inflammatory potential of a novel material on one hand and, on the other hand, non-healing osseous
defects to assess the healing potential of a bone substitute material have been developed. Sometimes the
use of more than one implantation site can be helpful to provide a wide range of information about a
new material [2].
Important markers for biocompatibility and inflammatory responses are the cell types appearing after
the implantation of foreign material. There, especially the role of foreign body giant cells (FBGC) is
discussed controversial in the pertinent literature, such that it is not clear whether their presence marks
an incompatibility of the biomaterial, or whether it belongs to a normal degradation behavior of modern,
resorbable biomaterials.
This publication is highlighting the different views currently existing about the function of FBGC that
appear in response to biomaterials at the implantation sites. A short overview of the general classes of
biomaterials, where FBGC may appear as cellular response, is added for clarity, but may not be
complete.
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Abstract: Skeletal defects may result from traumatic, infectious, congenital or neoplastic processes and are considered to 
be a challenge for reconstructive surgery. Although the autologous bone graft is still the “gold standard”, there is continu-
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composition of the material also –inductive ability, as well as for their long-term biocompatibility in bone. Serving this 
purpose various bone healing models to test osteocompatibility and inflammatory potential of a novel material on one 
hand and, on the other hand, non-healing osseous defects to assess the healing potential of a bone substitute material have 
been developed. Sometimes the use of more than one implantation site can be helpful to provide a wide range of informa-
tion about a new material [2]. 
Important markers for biocompatibility and inflammatory responses are the cell types appearing after the implantation of 
foreign material. There, especially the role of foreign body giant cells (FBGC) is discussed controversial in the pertinent 
literature, such that it is not clear whether their presence marks an incompatibility of the biomaterial, or whether it belongs 
to a normal degradation behavior of modern, resorbable biomaterials. 
This publication is highlighting the different views currently existing about the function of FBGC that appear in response 
to biomaterials at the implantation sites. A short overview of the general classes of biomaterials, where FBGC may appear 
as cellular response, is added for clarity, but may not be complete. 
BONE SUBSTITUTES 
Autografts 
 Autografts are still the method of choice to substitute 
damaged or lost bone. The transplanted bone is largely ne-
crotic and acts as a scaffold for the ingrowth of granulation 
tissue containing osteoprogenitor cells. Under the influence 
of local factors (cytokines, etc) these osteoprogenitor cells 
differentiate into osteoblasts that are responsible for new 
bone formation. At the same time the graft matrix is resorbed 
through osteoclasts. This process of graft resorption occur-
ring parallel to bone formation was already discovered by 
Phemister in 1914 [3], who named it “creeping substitution”. 
Biomaterials as Bone Substitutes 
 Bone substitute materials increasingly replace the use of 
autografts and can be divided into three major classes: poly-
mers, ceramics and natural materials. Nowadays they are 
used either alone or in combinations called composites [4]. 
Regardless of their composition, once they are implanted in 
bone, they also undergo the process of creeping substitution, 
although the speed and rate of this process may vary accord-
ing to their composition [5]. 
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Polymers 
 Synthetic polymers represent the largest class of biomate-
rials useful in applications in both, soft and hard tissue. They 
can be hydrophobic like silicone rubber (SR), polypropylene 
(PP), polyethylene (PE) and polymethylmetacrylate 
(PMMA), or water swelling or even water soluble like poly-
ethylene glycol (PEG). Some of them are degradable, others 
remain almost unchanged within the body. Polymers are 
long chained molecules consisting of a large number of 
small repeating units [6]. They can be amorphous or 
semicrystalline and their surfaces may be modified chemi-
cally and biochemically. 
 PMMA, to cite the most important polymer in current 
orthopedics, is a permanent bone substitute material which is 
frequently used to improve the anchorage of fracture fixation 
devices and joint replacement prostheses. It is also used in 
vertebroplasty in severe cases of impact fractures of the ver-
tebral body due to osteoporosis or neoplasm [7, 8]. Although 
this material has proven its usefulness in these applications, 
on the other hand it poorly osseointegrates even possibly 
disturbing bone healing and remodeling through its genuine 
inert properties. Additionally tissue necrosis may be caused 
through heat production up to 80°C while curing and by cre-
ating monomer toxicity [9, 10]. In combination with primary 
(micro-)mechanical instability these properties may lead to 
the formation of an interface membrane and subsequent 
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aseptic loosening [11-13]. Despite all those concerns, 
PMMA is still the most frequently used polymer bone ce-
ment in Europe [14]. 
 Hydrogels are novel polymers that gained more popular-
ity in recent years. As an example for degradable water con-
taining substances they can be injectible and of different 
water contents. They can consist of Poly-(ethylene glycol) 
[15], or gelatine [16-18]. 
 They are used experimentally and clinically as biomateri-
als for the controlled release of bone regeneration activity 
enhancing substances like Transforming Growth factor 
(TGF)-beta 1, Insulin-like growth factor (IGF)-1 and bone 
morphogenetic protein-2 [19-22] Furthermore, hydrogels can 
also be used as scaffolds and carriers for osteoprogenitor 
[23] and other cells like chondrocytes, fibroblasts and mes-
enchymal stromal cells. 
Ceramics 
 Ceramics are a large family of inorganic/non-metallic 
compositions with a wide range of characteristics depending 
on the processing method used. They can be dense, porous or 
non-porous and resorbable like tricalcium-phosphate [24], 
porous, inert and lead to bone ingrowth like hydroxyapatite-
coated porous metals, or dense, non-porous, surface active 
materials, that attach to the bone by chemical bonding like 
hydroxyapatite. In this chapter only the most frequently used 
ceramics are cited as examples. 
 Calcium phosphates represent a group of materials, 
where their properties depend on the calcium-phosphate ratio 
and modification of crystallinity and porosity. They are bio-
compatible, osseoconductive and degradable [25, 26] by 
extracellular dissolution of the calcium orthophosphate mate-
rial [27] and by a cell mediated resorption [28] similar to the 
bone remodelling or bone substitution observed with auto-
grafts [3]. Their degradation time may last up to years, de-
pending on the type of material. 
 Calcium phosphate ceramic blocks are brittle, highly 
susceptible to fatigue fractures and therefore of limited use 
in complex weight bearing locations [29]. Furthermore, their 
preset structure may render it difficult to adapt them to local 
defect sites. If used in blocks, their shape may not be corre-
sponding to the original bone defect and if used as granules 
it may be impossible to keep them at the implantation site. 
 Calcium phosphate cements can overcome this problems 
partially as they can be administered in paste form and in-
jected into bone defects, which makes adaptation to local 
requirements very easy. In addition, they can be adminis-
tered through the tissues without the need of open ap-
proaches to the injection sites. They harden without eleva-
tion of temperature. Depending on the individual composi-
tion and pH the cement setting results in brushite-cement 
(pH  4,2) or hydroxyapatite (pH > 4,2) [30]. There are more 
than 100 different formulations of calcium orthophosphate 
cements available, which can be divided into four classes: 
dicalciumphosphate dihydrate, calcium and magnesium 
phosphates, octocalciumphosphate and non-stoichiometric 
apatite cements [31]. 
 The use of ß-tricalcium phosphate (ß-TCP) is limited by 
its unpredictable rate of resorption and also its biocompati-
bility is discussed controversary. Levin [32] reported the 
presence of giant cells when tricalcium phosphate was im-
planted, whereas Jarcho [33] to the contrary stated, that there 
was no foreign body cell response. On the other hand, there 
is consense about ist osteoconductive properties [28, 33, 34]. 
 Dicalciumphosphate is one of the most soluble of calci-
umphosphate phases and can be used when quick degrada-
tion is required [35]. All cements of this group are the prod-
uct of an acid-base reaction and it shows good osteoconduc-
tive properties. Despite the setting pH being quite low, tissue 
necrosis as a response has not been detected [31]. 
 Hydroxyapatite is used as implant coating [36], granules 
[37, 38] and in block structure [39]. It has a similar chemical 
composition as the mineral fraction of bone and attaches 
close to hard tissues. It is able to fill gaps between bone and 
implant up to 2 mm and stimulates bone ingrowth even in 
osteoporotic bone [40]. In contrast to ß-TCP, hydroxyapatite 
bone substitutes are considered non-resorbable. However, 
this is only partially true since also hydroxyapatite substi-
tutes degrade in vivo, albeit much slower compared to ß-TCP 
or brushite compositions [30, 41, 42]. 
 Hydroxyapatite-coated implants integrate well with the 
bone healing process [39, 43]. This characteristic, called 
“osteophilic” [36], provides a good substrate for osteoblasts. 
The use of hydroxyapatite as a coating of implants, there-
fore, is quite common. However, some authors found out, 
that it can lead to osteolysis when it is exposed to bone mar-
row and soft tissues [44]. There, the hydroxyapatite wear 
debris is thought as the main cause for implant failure [45] as 
its phagocytosis stimulates the release of cytokines. Subse-
quently these products are held responsible for (granuloma-
tous) inflammation, disturbance in bone remodelling and 
local osteolysis. 
 Natural materials: Natural polymers such as silk, cellu-
lose, collagen, proteoglycans, glycosaminoglycans and 
elastin are often quite similar to natural occurring substances 
which makes it easy for the body to recognize and degrade 
these materials by physiological mechanisms [46]. On the 
other hand they are immunogenic and the technological ma-
nipulation to avoid tissue reactions are elaborate and some-
times cost intensive. 
HOST RESPONSE 
 Implanted biomaterials are always recognized as foreign 
by the body, independent on how elaborate the biocompati-
bility was previously tested. All medical devices and pros-
theses implanted in connective tissue immediately induce an 
initial host response to act against the foreign body. The type 
of implant-tissue response can be graded according to Hench 
[24]: if the material is i) toxic, the surrounding tissue dies, ii) 
nontoxic and biologically inactive (nearly inert), a fibrous 
tissue of variable thickness forms, iii) non-toxic and biologi-
cally active (bioactive), an interfacial bond forms, and iv) 
non-toxic and dissolves, the surrounding tissue replaces it. 
 This acute inflammatory reaction resembles in large the 
normal wound and fracture healing process [47] and consists 
of cellular and molecular components. The magnitude [48] 
and duration of the inflammatory process has a determining 
influence on the stability and compatibility of the implanted 
medical devices. 
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 The foreign body reaction starts within seconds or min-
utes after tissue contact [49] with a conditioning film of gly-
coproteinaceous materials called “opsonins” on the surface 
of the implanted device [50]. Albumin, fibrinogen, immun-
globulin G and complement components are the most abun-
dant proteins on the surface of polymers [51]. While the 
deposition of fibrinogen and mainly immunogloblins is con-
sidered as an active process and tissue response to the for-
eign material, the deposition of albumin probably can be 
ruled out as being part of this reaction, because it seems to 
more passivate the surface of implants [49]. Nevertheless, 
some authors found out, that the entire protein layer seems 
not to be critical for the immune response as either IgG defi-
cient or complement depleted mice showed a regular reac-
tion against foreign bodies [52]. 
 This layer, recognized by the integrin receptors present 
on neutrophils and macrophages, plays an important role 
since it converts the implant into a biologically recognizable 
material [53]. It initializes monocyte attraction and migration 
through the endothelium through mast cell activation and 
associated histamin release as the next step of host response 
[54]. 
 This is followed by a fibroblast invasion and synthesis of 
extracellular matrix through these activated fibroblasts [55]. 
It ends up in an inner layer of macrophages and/or foreign 
body cells with an outside secondary zone of layered fibro-
blasts and connective tissue [56] surrounding the implanted 
material. This reaction is unique and does not seem to de-
pend on the type of implant [57]. The magnitude of the pe-
riprosthetic or peri-material reaction and the thickness of the 
inflammatory layer is said to be an index for the biocompati-
bility of the implant [58] as it depends on the chemical and 
topographical nature of the surface of the device. 
 Most of the routinely applied biomaterials have excellent 
characteristics related to biocompatibility in bulk form. 
Sometimes the foreign body reaction is clinically first seen 
when the implant is disintegrated [59-61]. The failure of im-
plants seems to be connected with the interfacial accumula-
tion of wear particles in case of metals and degradation 
products in combination with biodegradable materials [27, 
62-64]. The discussion about biocompatibility is controver-
sial [58, 65, 66], but there is a certain agreement, that the 
extent and intensity of tissue reaction defines the biofunc-
tionality of an implant, rather than the response by itself 
[67]. In other words: not the lack of host reaction, but the 
appropriateness of the answer is important. 
 The question addressed in this article was, how this ap-
propriateness could be defined through the appearance of 
different cells in the implantation site. 
CELLULAR REACTION AFTER BIOMATERIAL 
IMPLANTATION 
 In bone healing processes connected with the implanta-
tion of foreign materials a specialized group of cell types 
with different characteristic abilities can be found (Fig. 1). 
 The first cells attaching to the implanted material are the 
fibroblasts. They produce immature collagen that is laid 
down onto the surface of the implant [51, 55, 56, 68, 69]. 
IMPLANTATION OF BIOMATERIAL 
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Fig. (1). Inflammatory rection and foreign body giant cell reaction (Modified after [69]). 
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These cells are recruited from the mesenchymal tissue sur-
rounding the implanted material or fracture site upon release 
of signal transduction molecules of the resident bone and 
hematoma cells. These signals are also responsible for initi-
ating the cascade of bone formation and resorption pertinent 
to fracture and/or defect healing, resp. bone remodeling [69]. 
 Among the bone forming cell types, osteoprogenitor cells 
are detected at the inner layer of the periosteum. These cells 
can differentiate into osteoblasts under the influence of Bone 
morphogenetic protein (BMP)-2, which apart from os-
teogenesis also stimulates angiogenesis in bone healing. Un-
der the condition of low oxygen tension the progenitor cells 
may also differentiate into chondrogenic cells. Osteoblasts, 
derived from osteoprogenitor cells synthesize the organic 
components of the bone, such as collagen, proteoglycan and 
glycoproteins (Fig. 2). After their differentiation they ex-
press bone specific alkaline phosphatase (ALP), which there-
fore, is a late marker of bone formation. Osteocytes derived 
from osteoblasts are mature bone cells, that became trapped 
in their lacunae. Osteocytes keep in contact to each other by 
cytoplasmatic processes, through which ions and small 





Fig. (2a,b). Seams of osteoblasts (arrows) close to a natural bone 
substitute (Kossa 20x, 10x).  
 Cells responsible for bone (or material) resorption are 
connected to the osteoclast lineage. The precursor cells of 
osteoclasts come from the bone marrow and are called 
granulocyte-macrophage progenitor cells [71]. They are 
thought to derive from the blood macrophages. Upon stimu-
lation by local signalling molecules, mediators and cytokines 
(such as receptor activator of nuclear factor-B ligand 
(RANKL), prostaglandin E2, interleukin (IL)-1 and 6) these 
originally mononuclear cells fuse to become multinucleated 
cells generally found on mineralized surfaces in bone (Fig. 
3) Osteoclasts are responsible for resorbing bone, especially 






Fig. (3a,b). Osteoclasts degrading a natural bone substitute material 
(arrows). (Kossa 20x, Toluidinblue 10x). 
been produced, such that this immature substitute can be 
replaced by lamellar bone. It is not always possible to distin-
guish osteoclasts from foreign body cells (FBGC) with cer-
tainty. Osteoclasts resemble foreign body giant cells mor-
phologically but have calcitonin receptors on their surface. 
To distinguish osteoclasts from FBGCs immunostaining of 
osteocalcin receptors would, therefore, be the modern 
method of choice. Formerly, special stainings for the tartrate-
resistant acid phosphatase (TRAP): TRAP [72] were rou-
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tinely performed for this task. Some authors found out, that 
the TRAP-coloration was not entirely specific for osteoclasts 
[73]. However, technical problems with immunostainings in 
bone especially in larger animal species and in combination 
with biomaterials, where bone samples have to be embedded 
in plastic sections, make it impossible to successfully use 
osteocalcin antibodies for osteoclast identification. 
 Osteoclasts can carry out the highly specialized function 
of lacunar bone resorption, but it is generally believed that 
they do not phagocytose particles of biomaterials at the 
bone-implant interface [74]. However other investigations 
show, that they are capable of phagocytosing both polymeric 
and metallic biomaterial particles. This lead to the conclu-
sion, that not all multinucleated cells, that contain wear par-
ticles and can be found next to osteolysis are FBGC [75]. 
 In the line of defense, lymphocytes and plasma cells pro-
duce antibodies to protect the body against foreign antigens, 
they are seen in greater numbers in areas of more chronic 
inflammation and where foreign substances have entered the 
tissue [56, 65, 68, 69, 76-80] (Fig. 1). Neutrophils participate 
in the foreign body reaction by releasing lytic enzymes [81]. 
Usually neutrophil polymorphs are found in the immediate 
period after lesions were created for wound debridement, but 
mark the presence of (sub-)clinical bacterial infection if 
found later in the wound healing period. 
 In addition, two other cell types are also especially inter-
esting considering cellular defense mechanism to foreign 
material: macrophages and foreign body giant cells (FBGC). 
There is no general agreement in the literature about their 
character of being inflammatory and thus, negative for the 
process, or just belonging to a normal response in degrading 
materials. 
 Macrophages derive from the mononuclear phagocyte 
system. All members of that system arise from a common 
stem cell in the bone marrow, possess lysosomes and are 
capable of phagozytosis. In the first few days after a fracture 
has occurred or a bone defect has been produced, granulation 
tissue grows in between the fracture ends or edges respec-
tively. As mentioned above, neutrophil polymorphs are the 
type of cells which can be found most frequently in this pe-
riod. The macrophage derived interleukin-1 may cause neu-
trophil infiltration, induce angiogenesis and antibody pro-
duction and lymphokine synthesis [82]. Later more chronic 
inflammatory cells like macrophages are found, which re-
move red cells, necrotic fat and tissue debris [76]. These are 
transformed monocytes which arrive at the implantation site 
via a complex pathway of chemotactic and chemokinetic 
agents like mast cells/histamine [54], and Tumor Necrosis 
Factor (TNF) -alpha [83] release, complement factors, lym-
phokines, chemokines, platelet factors, leukotrienes and 
eventually bacterial fragments [84]. They adhere to the bio-
materials via several adhesion ligand-receptor superfamilies 
[80], such as with an integrin binding [68]. Certain biomate-
rial-adsorbed proteins promote monocyte adhesion. The 
most active in this regard are fibrinogen, fibronectin and 
immunglobulin G [85-87]. 
 After adhesion they transform into macrophages which 
are characterized by cell enlargement and an increased secre-
tion of inflammatory mediators (cytokines and chemokines), 
an increased expression of membrane proteins (e.g. in-
tegrins) [88, 89] and the expression of angiogenic and other 
growth factors [80]. The released factors attract different cell 
types like additional macrophages, neutrophils, fibroblasts 
and other cells [89-92]. 
 Macrophages are cells that secrete factors to promote 
physiological wound healing. Some of the macrophages may 
also function as accessory antigen-presenting cells [93]. On 
the other hand, they can be the central cellular mediators of 
the chronic inflammatory response to foreign materials [56] 
by secreting monocyte chemoattractant protein-1 (MCP-1) 
contributing to the development of the foreign body reaction 
[94], disturbing wound healing and ultimately contributing to 
implant failure. 
 Macrophages phagocytose damaged cells, cellular debris 
and foreign substances and digest the ingested material by 
hydrolytic enzymes in their lysosomes. While this mecha-
nism functions for several biomaterials in the same way, 
their enzymatic apparatus is not able to degrade synthetic 
polymers [95]. Some authors consider the presence of 
macrophages around or near biomaterials to be part of a 
chronic inflammatory reaction, whereas others relate to them 
as part of the normal degradation behaviour, at least in case 
of degradable materials in bone [27, 62, 96, 97] (Fig. 4). 
 Macrophages also modulate the tissue reaction through 
production of interleukins, growth factors and other bioac-
tive agents and most importantly they are the precursors of 
osteoclasts and foreign body giant cells. The role of RANKL 
and what triggers the fusion and further differentiation into 
osteoclasts or foreign body giant cells is not entirely clear 
[96, 97]. 
 Mechanical wear of implants (the smaller the more) [45] 
activate macrophages to phagocytosis which in turn induces 
secretion of TNF-, IL-1ß, IL-6 and prostaglandin (PGE)2 
[45, 98] that stimulates differentiation of osteoclast precur-
sors into mature osteoclasts [99]. This effect leads to bone 
resorption and in excess can induce implant failure [100]. 
While in debate whether osteoclasts contain foreign material 
in their cytoplasm, it also has been shown, that macrophages, 
which have phagocytosed particles, are capable of osteoclast 
differentiation [101]. 
 Interaction of macrophages and lymphocytes are com-
plementary. It is likely that the adhesion of macrophages to a 
surface also is the initial signal to activate the lymphocytes 
which in turn release molecules that furthermore influence 
macrophage activity [77] and fusion [81, 102-104]. There-
fore, the presence and activity of lymphocytes may be a de-
termining factor in excessive resorption behaviour or ulti-
mate biocompatibility questions. 
 Macrophages also modulate in the process of tissue re-
pair. Since they derive from the vascular system, a good vas-
cularity, therefore, is one of the important factors [105]. 
Animals depleted of macrophages or having received anti-
macrophage monoclonal antibodies show deficient wound 
healing [106]. 
 Foreign body giant cells are present in cases of bone de-
fect healing with or without autologous bone grafts and play 
a significant role if biomaterials are applied. In case of bio-
materials and bone controversy exists in whether they are 
part of normal bone healing or material degradation, or 
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Fig. (4). Biocompatibility study of a biomaterial as bone substitute 
in sheep bone. Macrophages (arrows) with ingested foreign mate-
rial. (a: Kossa 20x, b: Kossa 40x). 
 Under chronic inflammatory conditions and if the matter 
to be disposed is very large (bigger than the diameter of a 
macrophage [27], than 80 m [95], 5m [44], 12 m [35]), 
or indigestible for osteoclasts [107, 108], several macro-
phages fuse to form a foreign body giant cell [109]. Ander-
son [69], in contrary, has the opinion that „the presence of 
mononuclear cells, including lymphocytes and plasma cells, 
is considered chronic inflammation, whereas the foreign 
body reaction with the development of granulation tissue is 
considered the normal wound healing response to implanted 
biomaterials“. His view in regard to foreign bodies is similar 
to Lassus et al. who considers macrophages to be part of the 
normal degradation process [96, 97]. 
 The mechanism of cellular fusion of macrophages to 
FBGC is similar to phagocytosis and is mediated by several 
mediators [110, 111], but little is known regarding the bio-
logical responses which are considered to influence the tran-
sition to FBGC development [69]. 
 It can lead to very large cells (up to 1 mm2) with hun-
dreds of nuclei [112, 113]. FBGCs are also generally ob-
served in granulomas induced by bacterial pathogens, such 
as in tuberculosis or trichinellosis, which is probably the 
main reason for the negative association with their presence 
in tissue. 
 Cytokines like interleukin-4 and 13 are known as potent 
inductors of macrophage fusion into FBGC [103, 114, 115]. 
They also play a central role in cellular reactions which 
cause bone lysis around implants [116] as they modulate the 
balance between osteoblasts and osteoclasts [117]. The injec-
tion of anti-interleukin-4-antibody significantly decreased 
FBGC density on polyetherurethane ureas in vivo [102]. 
 Foreign body giant cells act to concentrate phagocytic 
and degradative activities at the host-implant interface. They 
ingest and dissolute implanted material intracellularly or by 
the release of degradative agents like lysosomal enzymes and 
reactive oxygen intermediates (ROIs) at the ventral cell sur-
face [118] in response to certain stimuli, whereby their 
phagocytic capacity can be as effective as macrophages 
[119]. They also can directly contribute to osteolysis by dif-
ferentiation into TRAP-positive osteoclast-like cells [120-
122]. 
 FBGC rapidly differentiate after the implantation and 
progressively decrease with time [123]. Their size depends 
on the intensity of the inflammatory response [124]. They 
resemble osteoclasts morphologically, such that both are 
multinucleated, are found near implant/bone contact and 
have a cytoplasm with many vacuoles (Fig. 5). FBGCs con-
tain great numbers of mitochondria of various size and oval 
or round nuclei. Rough endoplasmatic reticulum is found 
throughout the cytoplasm [125]. The osteoclast on the other 
hand is defined as possessing a resorbing apparatus consist-
ing of ruffled border and clear zone, expression of the tar-
trat–resistant acid phosphatase and the expression of calci-
tonin-receptors [125]. However, it has to be kept in mind that 
other authors question whether the TRAP-epitopes as well as 
other markers (such as calcitonin receptors) are specific for 
osteoclasts [73]. 
 
Fig. (5). Foreign body giant cell (arrow) close to implanted mate-
rial. (Kossa 40x). 
 One of the most important aspects in the evaluation of 
biomaterials is the degradation resistance, with the exception 
of the class of biodegradable polymers, that rely on enzymes, 
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acid or ROIs for degradation of the polymer matrix [126]. 
The discussion about the role of FBGCs is controversary 
with the main question being whether the presence of 
FBGCs near an implant is just a sign of biodegradability 
[126], therefore a part of normal bone healing and resorption 
after the implantation of a bone substitute, or a sign of insuf-
ficient biocompatibility, inflammation and implant failure? 
Both sides have valuable arguments ready which are outlined 
below. 
 The arguments in favour of the FBGC are that i) these 
cells are part of the normal wound healing response to im-
planted inert or biodegradable biomaterials [56, 127], ii) 
their presence does not impair bone formation [31], iii) the 
presence of FBGCs indicates a low degradability of the im-
planted substance [125, 128, 129], iv) FBGC in the absence 
of other inflammatory cells show a good biocompatibility 
[107], and most importantly v) macrophages and FBGCs 
mediate material resorption and fragmentation of biodegrad-
able implants [125, 129-131]. The latter is supported through 
the fact that resorbed material could be seen in intracyto-
plasmatic vacuoles by transmission electron microscopy 
[132]. Furthermore, the implantation bed of resorbable poly-
L-lactide (PLLA) plates and screws showed a “foreign body 
reaction without signs of inflammation”: only a few poly-
morph nuclear leucocytes were present and the remnants of 
the plates and screws were surrounded by connective tissue 
with macrophages, foreign body giant cells and fibrocytes. 
The foreign body reaction was thought to be evoked by very 
small particles (22 m) of disintegrated PLLA plates and 
screws [61] and the amount of the degraded material seems 
to influence the intensity of the foreign body reaction [133]. 
This view, that FBGC are responsible for the degradation of 
biomaterials, is further supported by the analyses of retrieved 
implants showing material surface cracks directly under ad-
herent FBGC [113]. If macrophages and foreign body cells 
are part of the normal wound healing process, the foreign 
body cells may persist for the lifetime of the implant, it is not 
known if activated or quiescent [69]. Biocompatibility may 
be in jeopardy, if the presence of a large mass of disinte-
grated material seems to “exceed the local tissue tolerance” 
[61]. Here, the question arises where the line has to be drawn 
for local tissue tolerance? 
 The arguments pointing towards FBGC being a a bad 
sign for tissue tolerance are that i) the fusion of specialized 
macrophages is induced by poorly tolerated foreign bodies 
[78, 112, 134], ii) avoiding monocyte or macrophage adhe-
sion and FBGC formation, inflammatory degradation could 
be minimized [135], iii) the presence of macrophages and 
FBGC is associated with structural and functional failure of 
the implant [136], and iv) FBGC seem to concentrate the 
phagocytic and degradative activities at the tissue-material 
interface and therefore are responsible for the damage and 
failure of the implant. For the latter the authors tested coat-
ing the surface of an implant with a material that promotes 
programmed cell death to inhibit the adhesion and fusion of 
macrophages into FBGCs [137]. 
 Fibrous capsule formation close or around an implanted 
biomaterial is frequently seen. The reasoning behind it is that 
if the implanted biomaterial cannot be ingested by macro-
phages and FBGCs (“frustrated phagocytosis”) the next best 
protection for the host seems to be the isolation of the for-
eign object. This can be achieved best by a layer of FBGC in 
a fibrous, quite avascular capsule limiting further interaction 
between host and implanted device. The capsule type de-
pends on the secreted cytokines [95, 138], the extent of in-
jury or defect created and the amount of provisional matrix 
[69]. 
 On one hand this fibrous capsule may indeed downsize 
the inflammatory reaction, but on the other hand in osseoin-
tegration processes can lead to device failure and restricted 
nutrient supply. Poor tissue device contact can lead to infec-
tion. A fibrous layer (so called interface membrane) between 
methylmethacrylate and an implant has shown to be morpho-
logically synovial-like [55]. In well fixated or coated [139] 
implants the interfacial membrane is thin with only some 
macrophagic aggregates. The quantity and quality of the 
fibrous scar tissue depends on the implantation technique 
and the prosthetic material used [11-13, 55]. 
INFLUENCES ON BIOCOMPATIBILITY AND FOR-
EIGN BODY RESPONSE 
 The type of biocompatibility and foreign body response 
depends on the chemical composition/surface character, 
morphology, localization of the implant the surgical tech-
nique and mechanical loading [140, 141]. Besides that, de-
gradability, hormonal and humoral influences play an impor-
tant role. 
Implant 
 Surface morphology: The implant surface-tissue interface 
is the most important relationship for biocompatibility in 
vivo especially in metallic implants but also in other bioma-
terials [81] as the surface character influences the nature and 
magnitude of the foreign body reaction [142]. The biocom-
patibility of an implant and the irritation of the surrounding 
tissue depends on different parameters like hydrophobic-
ity/hydrophilicity, wettability, surface charge, polarity, sur-
face energetics, mobility of the surface molecules and 
smoothness. Thereby it seems to depend more on physical 
attributes than on the implant`s chemical composition [65]. 
 The hydrophilic surface of hydrogels for example has a 
small amount of interfacial free energy to react with body 
fluids and this results in a low tendency for proteins and cells 
to adhere and grow onto these surfaces [143, 144]. 
 In the contrary Eriksson et al. [145] compared the heal-
ing response between hydrophilic and hydrophobic implant 
surfaces and found out, that the difference in the adherence 
of viable cells can be seen only initially. A certain roughness 
of an implant prevents excessive tissue motion and therefore 
results in a relatively thin soft tissue layer in comparison to 
the polished surface of the common stainless steel implants 
[146]. On the other hand the resulting surface enlargement 
can increase the risk for corrosion. 
 Cells do not adhere directly to the surface of synthetic 
implanted materials, but to extracellular matrix proteins. 
Implants coated with phosphorylcholine have been shown to 
reduce this protein adsorption and this resulted in a lower 
inflammatory response and a lower fibrous capsule thickness 
[139]. 
 Some authors refer to implant failure as a „small particle 
disease“ especially with metallic devices, because the inter-
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facial membrane is full of implant debris [63]. The physical 
characteristics of those particles play an important role in the 
resulting inflammatory reaction [45]. To avoid excessive 
particle formation mechanical biostability is especially im-
portant in implants that are planned to remain in the body for 
a long time [11-13]. 
 Materials composed of elements near to calcium and car-
bon in the periodic system are more biocompatible over time 
than others, because the body is composed mostly of those 
elements and water [81, 147]. If implants release drugs, the 
original situation may change again and the biocompatibility 
of the devices is affected by the bioactive compounds they 
deliver to the surrounding tissue [148]. 
 Hochuli-Vieira et al. [127] compared the body’s reaction 
on titanium plate and PLLA/polyglycolic-acid (PGA) im-
plant fixation after mandibular osteotomy in rabbits. The 
PLLA/PGA plates and screws were partially degraded after 
30-60 days. The implants were wrapped in connective tissue 
with some macrophages and FBGCs. No specific inflamma-
tory reaction was seen, but “some macrophages were in con-
tact with the screws” or “some scarce giant cells and macro-
phage cells around them” after 30 days of implantation. 
 An essential prerequisite for osteoconduction is the di-
rect, stable and extensive enough contact between host bone 
and the implanted material. One way to optimize the bio-
compatibility of an implant could be to coat the surface with 
a biocompatible film [149]. However, the best biocompati-
bility may be achieved when tissue can grow into the pores 
of the implanted material. As pores smaller than 50 m ex-
clude macrophages to clear bacteria away, pore size, there-
fore, should be about 60 m to avoid bacterial infection [30, 
62]. 
 On the other hand high-surface-to-volume-implants as 
porous devices are said to have higher ratios of macrophages 
and FBGCs in the implant site [69]. Bone ingrowth seems to 
increase with the size of the pores [150], at least initially but 
not in the long run. Pore dimensions of at least 10 m seems 
to be necessary for connective tissue ingrowth [151]. A 
minimal pore size of more than 100 m [24], even of 200-
400 m has been recommended [152], the latter being close 
to the average size (223 m) of the human osteon. 
 Degradability: Most synthetic polymers are degraded 
through hydrolysis, whereas most biopolymers such as col-
lagen are degraded through enzymatic attack. An optimal 
degradable scaffold material should be degraded and re-
sorbed at the same rate as the tissue grows into the implant 
and replaces it with natural bone [153] as nondegraded 
polymers are preventing complete ossification. Polylactides, 
for example, degrade slowly through hydrolyzation, and 
some residues can be found in the region of implantation up 
to 2 years [128]. 
 Bone healing studies have shown, that there is a “bone 
signal window” about 7 to 12 weeks after injury. After that 
time the natural bone healing signal disappears and a fibrous 
tissue scar will be the result. Therefore, the authors conclude 
that an implant should degrade up to 12 weeks, at least in 
bone [154]. 
 After the implantation of Ca/P-apatite-coated polylactone 
sponges and non-coated sponges as a control FBGC were 
observed in close contact to all implants. Their number 
seems to correlate with the amount of non-degraded and not 
on the composition of the material [128]. As mentioned 
above, it may be difficult to draw the line which rate of de-
gradability and subsequent FBGC formation is still tolerable 
as part of normal wound healing processes and where bioin-
compatibility issues start. 
 Any material implanted elicits a defensive process, but 
modern biomaterials can be well accepted by the tissue in 
which they are implanted. Their particular breakdown prod-
ucts on the other hand can induce a severe inflammatory 
reaction [63]. The cellular activity while PLLA plates are 
resorbed showed a dense layer of macrophages in the first 
few weeks and in the end stage of the resorption process 
after 104 to 143 weeks [155]. The changes in biomechanical 
properties and morphology due to the degradation may in-
tensify the foreign body reaction [156]. It has been stated by 
several authors that the accumulation of macrophages is a 
general biomaterial phenomenon related to degradable bio-
materials [157-160]. 
 Localisation: Biocompatibility depends on the surface 
structure of the medical device and, of course, also on the 
tissue, in which it is implanted [64, 161]. Medical devices 
implanted in different tissue types provoke a different reac-
tion. Here, the statement of Williams should be remembered, 
that “the unique cicumstances pertaining to individual cases 
have to be considered when defining biocompatibility” 
[162]. 
Surgical Technique/Implantation Model 
 There are two different models representing different 
principles to test novel materials in bone: a wound model, 
where spontaneous healing will occur in a short time, pro-
vides information about osteocompatibility and inflamma-
tory potential of a given material; and a model of large osse-
ous defects [163], that do not heal spontaneously. 
 The correct placement of an implant is of utmost impor-
tance, as post implantation mobility leads to chronic inflam-
mation with the development of a thick fibrous capsule with 
all its disadvantages [11-13]. 
Mechanical Loading 
 Bone is subjected to high strain [164, 165]. In its function 
of load bearing continuous microdamage to bone occurs 
[166] that constantly demands structure remodelling. As de-
scribed earlier this remodelling is mostly coordinated by 
bone forming cells (osteoblast, osteocytes and periostal 
cells), monocyte-derived osteoclasts and multinuclear cells. 
Extensive micromotion between implant and host bone leads 
to an intermediate layer between them. One has to keep in 
mind that this intermediate layer, also called interface mem-
brane, cannot be distinguished according to its primary cause 
such as biocompatibility and/or mechanical problems. Tissue 
composition and cellular components are more less identical 
in both cases and again, this thick and fibrous layer severely 
disturbs osseointegration of any implant. 
Hormones 
 Biomaterials inserted into bone normally elicit local and 
very seldom systemic responses. Therefore, the influence of 
systemic hormones may be negligible in most cases. Never-
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theless, hormones do influence the overall reaction of the 
immune system of a patient or an experimental animal which 
consequently may even have a – albeit relatively minor-local 
effect on immune response. Hormon concentrations may be 
directly related to the intensity of the immune response and 
as a result also to the tissue-implant response [148, 167]. 
High doses of steroid hormones could have significant down 
regulating effects on immune response [168]. High testos-
teron levels and low estrogen levels seem to depress immune 
function [169]. Estrogens are enhancers of humoral immu-
nity [105]. 
DISCUSSION AND CONCLUSIONS 
 Different cell types interact and lead to specific re-
sponses. Understanding these mechanisms may allow us 
altering or influencing these interactions [170] and finally 
arrive at implant surfaces that promote greater biocompati-
bility. Every unnatural implant induces a natural foreign 
body response, thus, it is not the response by itself but its 
extent and intensity on which the biocompatibility of a 
medical device is determined. Therefore, any definition of 
biocompatibility related to a certain material should be based 
on quantitative evaluation of the cell population surrounding 
the implant, not just on the types of cells that occur. 
 The presence of macrophages and FBGCs including the 
development of some granulation tissue is a normal answer. 
For degradable materials the action of those cells are 
needed, as the result of an implantation otherwise would be a 
thick fibrous capsule around the device with all its negative 
consequences. 
 For permanent materials macrophages and FBGCs are 
responsible for the removal of wear debris that even in the 
best of cases cannot be prevented completely. However, a 
material, that remains relatively stable and unchanged in the 
surrounding tissue and a low amount of wear particles will 
not induce a permanent foreign body reaction leading to im-
plant failure [11-13]. The body tissue seems to be capable of 
handling a continuous but minimal amount of wear debris 
without negative consequences, at least in bone. The appro-
priate and physiologic answer to the implantation seems to 
be the acute inflammatory reaction of the body with the 
mechanisms of macrophage and foreign body giant cell ac-
tion for both permanent and degradable materials which ends 
up in either the bodies acceptance of the non-degradable 
device or the removal of the degradable foreign body as fast 
as it can be replaced by new bone. Only persistent inflamma-
tory stimuli lead to chronic inflammation [69] including 
mononuclear cells like lymphocytes and plasma cells. Those 
are induced by the chemical and physical properties of the 
object or motion and if present in high numbers at the im-
plant site lead to implant failure and/or rejection. In fact, the 
natural reaction of the body to foreign (bio) materials is simi-
lar to granuloma formation seen with infectious diseases 
(e.g. tuberculosis, parasites, such as trichinella, etc.,). There, 
granulomas are graded according to their biological activity 
[171]. Granulomas with low activity just there in the tissue 
for years without causing harm [172, 173]. 
 However, since biomaterials are not infectious, but are 
either inert or fast or slowly degrading, resp. resorbing, it 
may be the extend of “granuloma” formation that determines 
their ultimate biocompatibility. A thin fibrous capsule may 
not be avoided and seemingly can be easily tolerated also in 
the bone. The same ist true for the presence of macrophages 
and/or FBGC. The material type, the speed of degradation 
and/or resorption may be responsible whether mainly 
macrophages alone will transport the material or whether 
fusion to FBGC resp. osteoclasts occurs [27, 55, 95-97, 117, 
138]. Even low numbers of lymphocytes and plasmacytes 
occasionally present within the fibrous tissue surrounding 
the implant may not seriously jeopardize material accep-
tance, whereas the combination of a thick fibrous capsule, 
high numbers of macrophages, osteoclasts and/or FBGC and 
the presence of lymphocytes and plasmacytes can be consid-
ered a tissue reaction associated with bioincompatibility. 
 Even though a low tissue reaction to biomaterials may be 
tolerable, improvement of biomaterial surfaces should still 
be attempted. Future work should be directed towards i) the 
inhibition of the (immune) cell adhesion to (non-degradable) 
implants by adding antibodies that bind to the integrin recep-
tor that recognizes the adhesion protein ii) the investigation 
of surface-chemistry for implanted (degradble or non-
degradable) biomaterials, that modulate short- and long-term 
adhesion of monocytes and macrophages and FBGC fusion 
to the special needs of each type of implant, iii) the option to 
manipulate macrophage behaviour by harnessing some of the 
beneficial functions, like the expression of angiogenic and 
other growth [53]. 
 Tissue responses may be further ameliorated and be kept 
to a minimum. Nevertheless, macrophages and FBGC may 
never be eliminated and may always be part of tissue re-
sponse towards degradable materials. 
ACKNOWLEDGEMENTS 
 The studies included in this publication were financed 
partly (grant for K.N.) by the National Centre of Compe-
tence (NCCR) CO-ME, Zurich, Switzerland granted by the 
Swiss National Funds (SNF). 
REFERENCES 
[1] Damien C, Parsons J. Bone graft and bone graft substitutes: A 
review of current technology and applications. J Appl Biomat 
1991; 2: 187-208. 
[2] Eid K, Zelicof S, Perona BP, Sledge CB, Glowacki J. Tissue reac-
tions to particles of bone-substitute materials in intraosseous and 
heterotopic sites in rats: discrimination of osteoinduction, osteo-
compatibility, and inflammation. J Orthop Res 2001; 19(5): 962-9. 
[3] Phemister DB. The fate of transplanted bone and regenerative 
power of its various constituents. Surg Gynecol Obstet 1914; 19(3): 
303-33. 
[4] Rechenberg Bv, Hofmann-Amtenbrink M, Meinel L. Introduction 
in biotechnology. In: Rüedi T, ed. AO philosophy and basic princi-
ples: AO/ASIF; 2006. 
[5] Rechenberg Bv, Auer J. Bone grafts and bone replacements. In: 
Auer J, Stick J, eds. Equine surgery: Saunders Elsevier; 2006. 
[6] Cooper SL, Visser SA, Hergenrother RW, Lamba NMK. Classes of 
materials used in Medicine: Polymers. In: Ratner B, Hoffmann AS, 
Schoen FJ, Lemons JE, eds. Biomaterials Science 2nd Ed. Oxford: 
Elsevier; 2004. 
[7] Brodano GB, Cappuccio M, Gasbarrini A, et al. Vertebroplasty in 
the treatment of vertebral metastases: clinical cases and review of 
the literature. Eur Rev Med Pharmacol Sci 2007;11(2): 91-100. 
[8] Manson NA, Phillips FM. Minimally invasive techniques for the 
treatment of osteoporotic vertebral fractures. Instr Course Lect 
2007; 56: 273-85. 
[9] Yablon I. The effect of methylmethacrylate on fracture healing. 
Clin Orthop 1976; (114): 358-63. 
Biocompatibility Issues with Modern Implants in Bone The Open Orthopaedics Journal, 2008, Volume 2    75 
[10] Revell P, Braden M, Freeman M. Review of the biological re-
sponse to a novel bone cement containing poly(ethyl methacrylate) 
and n-butyl methacrylate. Biomaterials 1998; 19: 1579-86. 
[11] El-Warrak A, Olmstead M, Apelt D. An animal model for interface 
tissue formation in cemented hip replacements. Vet Surg 2004; 
33(5): 495-504. 
[12] El-Warrak A, Olmstead M, Rechenberg Bv. A review of aspects of 
looseneng in total hip prosthesis. Vet Comparative Ortho Trauma-
tol 2001; 3: 115. 
[13] El-Warrak A, Olmstead M, Schneider R. An experimental animal 
model of aseptic loosening of hip prostheses in sheep to study early 
biochemical changes at the interface membrane. BMC Muscu-
loskelet Disord 2004; 5: 7. 
[14] Jagger D, Harrison A, Jandt K. The reinforcement of dentures. J 
Oral Rehabil 1999; 26: 185-94. 
[15] Varghese S, Hwang NS, Canver AC, Theprungsirikul P, Lin DW, 
Elisseeff J. Chondroitin sulfate based niches for chondrogenic dif-
ferentiation of mesenchymal stem cells. Matrix Biol 2008; 27(1): 
12-21. 
[16] Hokugo A, Sawada Y, Hokugo R, et al. Controlled release of plate-
let growth factors enhances bone regeneration at rabbit calvaria. 
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104(1): 
44-8. 
[17] Yamamoto M, Tabata Y, Hong L, Miyamoto S, Hashimoto N, 
Ikada Y. Bone regeneration by transforming growth factor beta1 re-
leased from a biodegradable hydrogel. J Control Release 2000; 
64(1-3): 133-42. 
[18] Yamamoto M, Takahashi Y, Tabata Y. Enhanced bone regenera-
tion at a segmental bone defect by controlled release of bone 
morphogenetic protein-2 from a biodegradable hydrogel. Tissue 
Eng 2006; 12(5): 1305-11. 
[19] Tabata Y, Yamada K, Hong L, Miyamoto S, Hashimoto N, Ikada 
Y. Skull bone regeneration in primates in response to basic fibro-
blast growth factor. J Neurosurg 1999; 91(5): 851-6. 
[20] Takahashi Y, Yamamoto M, Yamada K, Kawakami O, Tabata Y. 
Skull bone regeneration in nonhuman primates by controlled re-
lease of bone morphogenetic protein-2 from a biodegradable hy-
drogel. Tissue Eng 2007; 13(2): 293-300. 
[21] Kawaguchi H, Jingushi S, Izumi T, et al. Local application of re-
combinant human fibroblast growth factor-2 on bone repair: a 
dose-escalation prospective trial on patients with osteotomy. J Or-
thop Res 2007; 25(4): 480-7. 
[22] Yamamoto M, Takahashi Y, Tabata Y. Controlled release by bio-
degradable hydrogels enhances the ectopic bone formation of bone 
morphogenetic protein. Biomaterials 2003; 24(24): 4375-83. 
[23] Srouji S, Livne E. Bone marrow stem cells and biological scaffold 
for bone repair in aging and disease. Mech Ageing Dev 2005; 
126(2): 281-7. 
[24] Hench L, Best S. Ceramics, Glasses and Glass-Ceramics. In: Rat-
ner B, Hoffman A, Schoen FJ, Lemons JE, eds. Biomaterials Sci-
ence. 2nd Ed. San Diego: Elsevier; 2004. 
[25] Chow L. Calcium phosphate materials: reactor response. Adv Dent 
Res 1988; 2: 181-4. 
[26] Jarcho M. Biomaterials aspects of calcium phosphates: properties 
and applications. Dent Clin North Am 1986; 30: 25-47. 
[27] Theiss F, Apelt D, Brand B, et al. Biocompatibility and resorption 
of a brushite calcium phosphate cement. Biomaterials 2005; 26: 
4383-94. 
[28] Yuan H, Li Y, de Bruijn JD, de Groot K, Zhang X. Tissue re-
sponses of calcium phosphate cement: a study in dogs. Biomateri-
als 2000; 21(12): 1283-90. 
[29] Ignatius AA, Augat P, Ohnmacht M, Ponkinskyj P, Kock H, Claes 
L. A new bioresorbable polymer for screw augmentation in the os-
teosynthesis of osteoporotic cancellous bone: A biomechanical 
evaluation. J Biomed Mater Res 2001; 58: 254-60. 
[30] Bohner M, Van Landuyt P, Merkle H, Lemaitre J. Composition 
effects on the pH of a hydraulic calcium phosphate cement. J Mater 
Sci Mater Med 1997; 8: 352-79. 
[31] Frayssinet P, Gineste L, Conte P, Fages J, Rouquet N. Short-term 
implantation effects of a DCPD-based calcium phosphate cement. 
Biomaterials 1998; 19(11-12): 971-7. 
[32] Levin M, Getter L, Adrain J, Cutright D. Healing of periodontal 
defects with ceramic implants. J Clin Periodontol 1974; 1: 197-205. 
[33] Jarcho M. Calcium phosphate ceramics as hard tissue prosthetics. 
Clin Orthop 1981; 157: 259- 78. 
[34] Steinbrunner RL, Brown CE, Jr., Legan JJ, Kafrawy AH. Biocom-
patibility of two apatite cements. J Endod 1998; 24(5): 335-42. 
[35] Nancollas H. In vitro studies of calcium phosphate cristallisation. 
In: Mann S, Webb J, Williams R, eds. Biomineralization Chemical 
and biochemical perspectives. New York: VCH; 1989. p. 157-82. 
[36] Thomas K, Kay J, Cook S, Jarcho M. The effect of surface macro-
texture and hydroxyapatite coating on the mechanical strengths and 
histologic profiles of titanium implant materials. J Biomed Mater 
Res 1987; 21: 1395-414. 
[37] Byrd H, Hobar P, Shewmake K. Augmentation of the craniofacial 
skeleton with porous hydroxyapatite granules. Plast Reconstr Surg 
1993; 91: 15-22. 
[38] Satoh K, Nakatsuka K. Simplified procedure for aesthetic im-
provement of facial contour by maxillary augmentation using a po-
rous hydroxyapatite graft for maxillofacial deformity. Plast Re-
constr Surg 1996; 97: 338-44. 
[39] Ylinen P, Suuronen R, Taurio R, Tormala P, Rokkanen P. Use of 
hydroxylapatite/ polymer-composite in facial bone augmentation. 
An experimental study. Int J Oral Maxillofac Surg 2002; 31(4): 
405-9. 
[40] Geesink R. Osteoconductive coatings for total joint arthroplasty. 
Clin Orthop 2002; 395: 53-65. 
[41] Bohner M. Calcium orthophosphates in medicine: from ceramics to 
calcium phosphate cements. Injury 2000; 31(Suppl 4): 37-47. 
[42] Bohner M, Van Landuyt P, Trophardy G, Merkle H, Lemaitre J. 
Effect of several additives and their admixtures on the physico-
chemical properties of a calcium phophate cement. J Mater Sci Ma-
ter Med 2000; 11(2): 111-6. 
[43] Hong L, Hengchang X, de Groot K. Tensile strength of the inter-
face between hydroxyapatite and bone. J Biomed Mater Res 1992; 
26(1): 7-18. 
[44] Bloebaum RD, Dupont JA. Osteolysis from a press-fit hydroxyapa-
tite-coated implant. A case study. J Arthroplasty 1993 ; 8(2): 195-
202. 
[45] Laquerriere P, Grandjean-Laquerriere A, Jallot E, Balossier G, 
Frayssinet P, Guenounou M. Importance of hydroxyapatite parti-
cles characteristics on cytokines production by human monocytes 
in vitro. Biomaterials 2003; 24(16): 2739-47. 
[46] Yannas I. Classes of materials used in medicine: Natural materials. 
In: Ratner B, Hoffman A, Schoen F, Lemons J, eds. Biomaterials 
Science. 2nd Ed. San Diego: Elsevier; 2004. 
[47] Rosengren A, Wallman L, Danielsen N, Laurell T, Bjursten LM. 
Tissue reactions evoked by porous and plane surfaces made out of 
silicon and titanium. IEEE Trans Biomed Eng 2002; 49(4): 392-9. 
[48] Misiek D, Kent J, Carr R. Soft-tissue responses to hydroxyapatite 
particles of different shapes. J Oral Maxillofac Surg 1984; 42: 150-
60. 
[49] Sevastianov V. Role of protein adsorption in blood compatibility of 
polymers. Crit Rev Biocompat 1988; 44: 109-54. 
[50] Gristina A, Dobbins J, Giammara B, Lewis J, DeVries W. Bioma-
terial-centered sepsis and the total artificial heart. JAMA 1988; 
259: 870-4. 
[51] Anderson J, Bonfield T, Ziats N. Protein adsorption and cellular 
adhesion and activating on biomedical polymers. Int J Artif Org 
1990; 13: 375-82. 
[52] Tang L, Lucas A, Eaton J. Inflammatory responses to Dacron: role 
of surface adsorbed IgG. J Lab Clin Med 1993; 122: 292-300. 
[53] Horbett T. The role of adsorbed proteins in tissue response to bio-
materials. In: Ratner B, Hoffman A, Schoen FJ, Lemons JE, eds. 
Biomaterials Science 2nd Ed. San Diego: Elsevier; 2004. 
[54] Tang L, Jennings T, Eaton J. Mast cells mediate acute inflamma-
tory responses to implanted biomaterials. Proc Natl Acad Sci USA 
1998; 95: 8841-6. 
[55] Santavirta S, Gristina A, Konttinen YT. Cemented versus ce-
mentless hip arthroplasty. A review of prosthetic biocompatibility. 
Acta Orthop Scand 1992; 63(2): 225-32. 
[56] Anderson JM. Inflammatory response to implants. ASAIO Trans 
1988; 34(2): 101-7. 
[57] Santavirta S, Pajamäki J, Konttinen YT, Eskola A, Lindholm T. 
Proliferative cell response to the loosening of THR. A cytofluoro-
graphic cell cycle analysis. Arch Orthop Trauma Surg 1991; 111: 
43-6. 
[58] Ikarashi Y, Toyoda K, Ohsawa N. Comparative studies by cell 
culture and in vivo implantation test on the toxicity of natural rub-
ber later materials. J Biomed Mater Res 1992; 26: 339-56. 
76    The Open Orthopaedics Journal, 2008, Volume 2 Nuss and von Rechenberg 
[59] Moore JW, Brekke JH. Foreign body giant cell reaction related to 
placement of tetracyclin-treated polylactid acid: Report of 18 cases. 
J Oral Maxillofac Surg 1990; 48(8): 808-12. 
[60] Maguire JK, Coscia MF, Lynch MH. Foreign body reaction to 
polymeric debris following total hip arthroplasty. Clin Orthop Relat 
Res 1987; (216): 213-23. 
[61] Bergsma EJ, Rozema FR, Bos RR, de Bruijn WC. Foreign body 
reactions to resorbable poly(L-lactide) bone plates and screws used 
for the fixation of unstable zygomatic fractures. J Oral Maxillofac 
Surg 1993; 51(6): 666-70. 
[62] Apelt D, Theiss F, El-Warrak A, et al. In vivo behaviour of three 
different injectable hydraulic calcium phosphate cements. Biomate-
rials 2004; 25: 1439-51. 
[63] Galante JO, Lemons J, Spector M, Wilson PD Jr, Wright TM. The 
biologic effects of implant materials. J Orthop Res 1991; 9: 760-75. 
[64] St. John KR. Particulate debris from medical implants: mechanisms 
and formation and biological consequences. Philadelphia: Ameri-
can Society for Testing and Materials; 1992. 
[65] Boss JH, Shajrawi I, Aunullah J, Mendes DG. The relativity of 
biocompatibility. A critique of the concept of biocompatibility. Isr 
J Med Sci 1995; 31(4): 203-9. 
[66] Campbell CE, von Recum AF. Microtopography and soft tissue 
response. J Invest Surg 1989; 2: 51-74. 
[67] Williams DF. The development and control of the host response to 
implanted polymers. International Conference on Biomedical 
Polymers: From Molecular Design to clinical Applications; 1991; 
Jerusalem. UNESCO. 
[68] Anderson J. Inflammation and the foreign body response. Problems 
Gen Surg 1994; 11: 147-60. 
[69] Anderson J. Inflammation, wound healing and the foreign body 
response. In: Ratner B, Hoffmann A, Schoen FJ, Lemons JE, eds. 
Biomaterials Science 2nd Ed. San Diego: Elsevier; 2004. 
[70] Marks S, Popoff S. Bone cell biology. Am J Anat 1988; 183: 1-44. 
[71] Gartner L, Hiatt J. Color textbook of histology. 2nd Ed. Philadel-
phia: W.B Saunders Company; 2001. 
[72] Fallon M, Teitelbaum S. A simple procedure for the rapid his-
tologic diagnosis of metabolic bone disease. Calcif Tissue Int 1981; 
33: 281-3. 
[73] Kadoya K, Al-Saffar N, Kobayashi A, Revell P. The expresson of 
osteoclast-markers on foreign body giant cells. Bone Miner 1994; 
27: 85-96. 
[74] Willert H, Bertram H, Buchhorn G. Osteolysis in alloarthroplasty 
of the hip: the role of bone cement fragmentation Clin Orthop 
1990; 258: 108-21. 
[75] Wang W, Ferguson DJ, Quinn JM, Simpson AH, Athanasou NA. 
Biomaterial particle phagocytosis by bone-resorbing osteoclasts. J 
Bone Joint Surg Br 1997; 79(5): 849-56. 
[76] Athanasou NA. Colour atlas of bone, joint and soft tissue pathol-
ogy. New York: Oxford University Press, New York; 1999. 
[77] Brodbeck WG, Macewan M, Colton E, Meyerson H, Anderson JM. 
Lymphocytes and the foreign body response: lymphocyte en-
hancement of macrophage adhesion and fusion. J Biomed Mater 
Res 2005; 74(2): 222-9. 
[78] Coleman D, King R, Andrade J. The foreign body reaction: a 
chronic inflammatory response. J Biomed Mater Res 1974; 8: 199-
211. 
[79] Zeller JM. Surgical implants. Physiological response. Aorn J 1983; 
37(7): 1284-91. 
[80] Ziats NP, Miller KM, Anderson JM. In vitro and in vivo interac-
tions of cells with biomaterials. Biomaterials 1988; 9(1): 5-13. 
[81] Morehead JM, Holt GR. Soft-tissue response to synthetic biomate-
rials. Otolaryngol Clin North Am 1994; 27(1): 195-201. 
[82] Wewers M. Cytokines in health and disease. New York: Marcel 
Dekker; 1992. 
[83] Tang L, Chesney J, Sherry B, Eaton J. The pivotal roles of cytoki-
nes in the recruitment and adhesion of inflammatory cells to im-
planted biomaterials. Trans Soc Biomater 1997; 23: 127. 
[84] Remes A, Williams D. Chemotaxis and the inhibition of chemo-
taxis of human neutrophils in response to metal ions. J Mat Sci Mat 
Med 1990; 1: 26-32. 
[85] Tang L, Eaton J. Fibrin (ogen) mediates acute inflammatory re-
sponses to biomaterials. J Exp Med 1993; 178: 2147-56. 
[86] Shen M, Garcia I, Maier RV, Horbett TA. Effects of adsorbed 
proteins and surface chemistry on foreign body giant cell forma-
tion, tumor necrosis factor alpha release and procoagulant activity 
of monocytes. J Biomed Mater Res A 2004; 70(4): 533-41. 
[87] Jenney C, Anderson J. Adsorbed IgG:a potent adhesive substrate 
for human macrophages. J Biomed Mater Res 2000; 50: 281-90. 
[88] Audran R, Lesimple T, Delamaire M, Picot C, Van Damme J, 
Toujas L. Adhesion molecule expression and response to chemo-
tactic agents of human monocyte-derived macrophages. Clin Exp 
Immunol 1996; 103: 155-60. 
[89] Nathan C. Secretory products of macrophages. J Clin Invest 1987; 
79: 319-26. 
[90] Riches D, Chan E, Winston B. TNF-alpha induced regulation and 
signaling inmacrophages. Immunobiology 1996; 195: 477-90. 
[91] Montesaro R, Orci L, Vassalli P. Human endothelial cell cultures: 
phenotypic modulation by leukocyte interleukins. J Cell Physiol 
1985; 122(3): 424-34. 
[92] Schmidt J, Mizel S, Cohen D, Green I. Interleukin-1, a potential 
regulator of fibroblast proliferation. J Immunol 1982; 128: 673-8. 
[93] Goodman SB. Does the immune system play a role in loosening 
and osteolysis of total joint replacements? J Long Term Eff Med 
Implants 1996; 6(2): 91-101. 
[94] Hagerty RD, Salzmann DL, Kleinert LB, Williams SK. Cellular 
proliferation and macrophage population associated with implanted 
expanded polytetrafluoroethylene and polyethylene terephthalate. J 
Biomed Mater Res 2000; 49: 489-97. 
[95] Konttinen YT, Zhao D, Beklen A, et al. The microenvironment 
around total hip replacement prostheses. Clin Orthop Relat Res 
2005; (430): 28-38. 
[96] Lassus J, Konttinen Y, Li T. Aseptic loosening of total hip prosthe-
sis. In: Lindholm T. ed. Skeletal reconstruction and bioimplanta-
tion. Austin, Texas, USA: Landes Bioscience; 1997. 
[97] Lassus J, Salo J, Jiranek W, et al. Macrophages activation results in 
bone resorption. Clin Orthop Relat Res 1998; 352: 7-15. 
[98] Haynes D, Roger S, Hay S, Pearcy M, Howie D. The differences in 
toxicity and release of bone-resorbing mediators induced by tita-
nium and cobalt-chromium-alloy wear particles J Bone Jt Surg 
1993; 75A: 825-34. 
[99] Anderson J, Miller K. Biomaterial biocompatibility and the macro-
phage. Biomaterials 1984; 5: 5-10. 
[100] Sabokbar A, Kudo O, Athanasou NA. Two distinct cellular mecha-
nisms of osteoclast formation and bone resorption in periprosthetic 
osteolysis. J Orthop Res 2003; 21: 73-80. 
[101] Sabokbar A, Fujikawa Y, Murray DW, Athanasou NA. Radio-
opaque agents in bone cement increase bone resorption. J Bone 
Joint Surg Br 1997; 79(1): 129-34. 
[102] Kao W, Mc Nally AK, Hiltner A, Anderson J. Role for interleukin-
4 in foreign body giant cell formation on a polyetherurethane urea 
in vivo. J Biomed Mater Res 1995; 29: 1267-75. 
[103] McNally AK, Anderson JM. Interleukin-4 induces foreign body 
giant cells from human monocytes/makrophages. Am J Pathol 
1995; 147: 1487-99. 
[104] McInnis A, ERennick D. Interleukin-4 induces cultured mono-
cytes/macrophages to form multinucleated cells. J Exp Med 1988; 
167: 598-611. 
[105] Butler KR, Jr., Benghuzzi HA. Morphometric analysis of the hor-
monal effect on tissue-implant response associated with TCP bioce-
ramic implants. Biomed Sci Instrum 2003; 39: 535-40. 
[106] Leibovich S, Ross R. The role of the macrophage in wound repair. 
Am J Pathol 1975; 78: 71-91. 
[107] Muller-Mai C, Voigt C, Hering A, Rahmanzadeh R, Gross U. [Ma-
dreporic hydroxyapatite granulates for filling bone defects]. Unfall-
chirurg 2001; 104(3): 221-9. 
[108] Vogel M, Voigt C, Knabe C, Radlanski RJ, Gross UM, Muller-Mai 
CM. Development of multinuclear giant cells during the degrada-
tion of Bioglass particles in rabbits. J Biomed Mater Res A 2004; 
70(3): 370-9. 
[109] Murch A, Grounds M, Marshall C, Papadimitriou J. Direct evi-
dence that inflammatory multinucleate cells form by fusion. J 
Pathol 1982; 137: 177-80. 
[110] DeFife KM, Jenney CR, Colton E, Anderson JM. Disruption of 
filamentous actin inhibits human macrophage fusion. FASEB J 
1999; 13(8): 823-32. 
[111] Kazazi F, Chang J, Lopez A, Vadas M, Cunningham A. Interleu-
kin-4 and human immunodeficiency virus stimulate LFA-1-ICAM-
1-mediated aggregation of monocytes and subsequent giant cell 
formation. J Gen Virol 1994; 75: 2795-802. 
[112] Smetana K, Jr. Multinucleate foreign-body giant cell formation. 
Exp Mol Pathol 1987; 46: 258-65. 
Biocompatibility Issues with Modern Implants in Bone The Open Orthopaedics Journal, 2008, Volume 2    77 
[113] Zhao Q, Topham N, Anderson JM, Hiltner A, Lodoen G, Payet CR. 
Foreign-body giant cells and polyurethane biostability: in vivo cor-
relation of cell adhesion and surface cracking. J Biomed Mater Res 
1991; 25(2): 177-83. 
[114] Sorimachi K, Akimoto K, Tsuru K, Ieiri T, Niwa A. The involve-
ment of tumor necrosis factor in the multinukleation of macro-
phages. Cell Biol Int 1995; 19: 547-9. 
[115] Mittermayer C, Eblenkamp M, Richter HA, Zwadlo-Klarwasser G, 
Bhardwaj RS, Klosterhalfen B. Pathology of implants. Kongressbd 
Dtsch Ges Chir Kongr 2002; 119: 491-7. 
[116] Mohanty M. Cellular basis for failure of joint prosthesis. Biomed 
Mater Eng 1996; 6(3): 165-72. 
[117] Konttinen Y, Xu J, Patiala H. Cytokines in aseptic loosening of 
total hip replacement. Curr Orthop 1997; 11: 40-7. 
[118] Zhao Q, Agger M, Fitzpatrick M, et al. Cellular interactions with 
biomaterials: In vivo cracking of pre-stressed Pellethane 2363-80A. 
J Biomed Mat Res 1990; 24: 621-37. 
[119] Schlesinger L, Musson R, Johnston R. Functional and biochemical 
studies of multinucleated giant cells derived from the culture of 
human monocytes. J Exp Med 1984; 159: 1289-94. 
[120] Quinn J, Joiner C, Triffitt J, Athanasou N. Polymethylmethacry-
late-induced inflammatory macriphages resorb bone. J Bone Joint 
Surg (Br) 1992; 74: 652-8. 
[121] Pandey R, Quinn JM, Sabokbar A, Athanasou NA. Bisphosphonate 
inhibition of bone resorption induced by particulate biomaterial-
associated macrophages. Acta Orthop Scand 1996; 67(3): 221-8. 
[122] Sabokbar A, Pandey R, Quinn JM, Athanasou NA. Osteoclastic 
differentiation by mononuclear phagocytes containing biomaterial 
particles. Arch Orthop Trauma Surg 1998; 117(3): 136-40. 
[123] Kawaguchi H, Ogawa T, Shirakawa H, Okamoto H, Akisaka T. 
Ultrastructural and ultrscytochemical characteristics of 
multinucleated cells after hydroxyapatite implantation into rat 
periodontal tissue. J Periodontal Res 1992; 27: 48-54. 
[124] Chambers T, Spector W. Inflammatory giant cells. Immunobiology 
1982; 161: 283-9. 
[125] Dersot JM, Colombier ML, Lafont J, Baroukh B, Septier D, Saffar 
JL. Multinucleated giant cells elicited around hydroxyapatite parti-
cles implanted in craniotomy defects are not osteoclasts. Anat Rec 
1995; 242(2): 166-76. 
[126] Chu C. Biodegradable polymeric biomaterials: an overview. In: 
Bronzino J. The biomedical engeneering handbook. Boca Ranton, 
FL: CRC Press; 1995. p. 611-26. 
[127] Hochuli-Vieira E, Cabrini Gabrielli MA, Pereira-Filho VA, Gabri-
elli MF, Padilha JG. Rigid internal fixation with titanium versus 
bioresorbable miniplates in the repair of mandibular fractures in 
rabbits. Int J Oral Maxillofac Surg 2005; 34(2): 167-73. 
[128] Holmbom J, Sodergard A, Ekholm E, et al. Long-term evaluation 
of porous poly(epsilon-caprolactone-co-L-lactide) as a bone-filling 
material. J Biomed Mater Res A 2005; 75(2): 308-15. 
[129] Klein CP, Van der Lubbe H, Driessen AA, de Groot K, Van den 
Hoof A. Biodegradation behaviour of various calciumphosphate 
materials in subcutaneous tissue. In: Vincencini P, ed. Ceramics in 
surgery. Amsterdam: Elsevier; 1983. p. 105-15. 
[130] Dersot JM, Septier D, Llorens A, Saffar JL. Multinukleated giant 
cells-a time-related quantitative study in a rat skull defect. Cells 
Mater 1993; 3: 395-405. 
[131] Klein CP, de Groot K, Driessen AA, Van der Lubbe H. A compara-
tive study of different beta-whitlockite ceramics in rabbit cortical 
bone with regard to their biodegradation behaviour. Biomaterials 
1986; 7: 144-6. 
[132] Dupraz A, Delecrin J, Moreau A, Pilet P, Passuti N. Long-term 
bone response to particulate injectable ceramic. J Biomed Mater 
Res 1998; 42(3): 368-75. 
[133] Cutright DE, Hunsuck EE. Tissue reaction to the biodegradable 
polylactic acid suture. Oral Surg Oral Med Oral Pathol 1971;31(1): 
134-9. 
[134] Papadimitriou J, Sforsina D, Papaelias L. Kinetics of multinucleate 
giant cell formation and their modification by various agents in for-
eign body reaction. Am J Pathol 1973; 73: 349-64. 
[135] Jenney CR, Anderson JM. Effects of surface-coupled polyethylene 
oxide on human macrophage adhesion and foreign body giant cell 
formation in vitro. J Biomed Mater Res 1999; 44(2): 206-16. 
[136] Stokes K, McVenes R, Anderson J. Polyurethane Elastomer 
Biostability. J Biomater Appl 1995; 9: 321-54. 
[137] Brodbeck WG, Shive MS, Colton E, Nakayama Y, Matsuda T, 
Anderson JM. Influence of biomaterial surface chemistry on the 
apoptosis of adherent cells. J Biomed Mater Res 2001; 55(4): 661-
8. 
[138] Santavirta S, Hoikka V, Eskola A. Aggressive granulomatous le-
sion in cementless total hip arthroplasty. J Bone Joint Surg 1990; 
72: 980-4. 
[139] Goreish HH, Lewis AL, Rose S, Lloyd AW. The effect of phos-
phorylcholine-coated materials on the inflammatory response and 
fibrous capsule formation: in vitro and in vivo observations. J Bio-
med Mater Res A 2004; 68(1): 1-9. 
[140] Thomsen P, Ericson L. Inflammatory cell response to bon implant 
surfaces. In: Davies J. The Bone-Biomaterial Interface. Toronto, 
Canada: University Toronto Press; 1991. 
[141] Branemark P, Lausmaa J, Ericson L, Thomsen P, Branemark R, 
Skalak R. Anatomy of osseointegration and the tranfer of load. In: 
Foneseca R, Davis W. Reconstructive preprosthetic oral and maxil-
lofacial surgery. Philadelphia, PA: Saunders; 1995. pp. 165-224. 
[142] Hench L, Wilson J. Surface-active biomaterials. Science 1984; 226: 
630-6. 
[143] Cadee JA, Van Luyn MJ, Brouwer LA, et al. In vivo biocompatibil-
ity of dextran-based hydrogels. J Biomed Mater Res 2000; 50(3): 
397-404. 
[144] Jeyanthi R, Rao KP. In vivo biocompatibility of collagen-
poly(hydroxyethyl methacrylate) hydrogels. Biomaterials 1990; 
11(4): 238-43. 
[145] Eriksson C, Nygren H, Ohlson K. Implantation of hydrophilic and 
hydrophobic titanium discs in rat tibia: cellular reactions on the sur-
faces during the first 3 weeks in bone. Biomaterials 2004; 25(19): 
4759-66. 
[146] Ungersbock A, Pohler O, Perren SM. Evaluation of the soft tissue 
interface at titanium implants with different surface treatments: ex-
perimental study on rabbits. Biomed Mater Eng 1994; 4(4): 317-25. 
[147] Costantino P, CD F, Lane A. Synthetic biomaterials in facial plastic 
and reconstructive surgery. Facial Plast Surg 1993; 9: 1-15. 
[148] Butler KR Jr., Benghuzzi HA. Immunohistochemical detection of 
cytokine expression in tissue-implant response associated with TCP 
bioceramic implants loaded with steroid hormones. Biomed Sci In-
strum 2003; 39: 541-6. 
[149] Bocchiotti G, Verna G, Fracalvieri M, Fanton E, Datta G, Robotti 
E. Carbofilm-covered prostheses in plastic surgery: preliminary ob-
servations. Plast Reconstr Surg 1993; 91(1): 80-8; discussion 9-90. 
[150] Van Blitterswijk CA, Bakker D, Hesseling SC, Koerten HK. Reac-
tions of cells at implant surfaces. Biomaterials 1991; 12(2): 187-93. 
[151] Von Recum A, Van Kooten T. The influence of microtopography 
on cellular response and the implications for silicone implants. J 
Biomater Sci Polym Edn 1995; 7: 181-98. 
[152] Holmes R. Bone regeneration within a coralline hydroxyapatite 
implant. Plast Reconstr Surg 1979; 63: 626-33. 
[153] Hutmacher D. Scaffolds in tissue engineering bone and cartilage. 
Biomaterials 2000; 21: 2529-43. 
[154] Ekholm E, Hietaniemi K, Määttä A, Vouorio E, Paavolainen P, 
Penttinen R. Extended expression of cartilage components in ex-
perimental pseudarthrosis. Connect Tissue Res 1995; 31: 211-8. 
[155] Bos RR, Rozema FR, Boering G, et al. Degradation of and tissue 
reaction to biodegradable poly(L-lactide) for use as internal fixa-
tion of fractures: a study in rats. Biomaterials 1991; 12(1): 32-6. 
[156] Sevastjanova N, Mansurova L, Dombrovska L, Slutkii L. Bio-
chemical characterization of connective tissue reaction to synthetic 
polymer implants. Biomaterials 1987; 8: 242-7. 
[157] Koerten H, Van Blitterswijk CA, Hesseling SC, Grote JJ. Trace 
element accumulation after macrophage/material interactions. In: 
Heimke G, Soltesz U, Lee A, eds. Clinical implant materials. Am-
sterdam: Elsevier; 1990. p. 219. 
[158] Bakker D, Van Blitterswijk CA, Hesseling SC, Grote JJ. Effect of 
implantation site on phagocyte/polymer interaction and fibrous 
capsule formation. Biomaterials 1988; 9(1): 14-23. 
[159] Bakker D, Van Blitterswijk CA, Hesseling SC, Grote JJ. Biodegra-
dation and phagocyte/polymer interaction. In: Williams K, Lasser 
T. Interfaces in medicine and mechanics. Trowbridge: Dotesios; 
1989. p. 110. 
[160] Van Blitterswijk CA, Koerten HK, Bakker D, Hesseling SC, Grote 
JJ. Biodegradation dependent trace element accumulation: a study 
on calcium phosphate ceramics and polymers. In: Williams K, 
Lesser T, eds. Interfaces in medicine and mechanics. Trowbridge: 
Dotesios; 1989. p. 110. 
78    The Open Orthopaedics Journal, 2008, Volume 2 Nuss and von Rechenberg 
[161] Boss JH, Shajravi I, Soudry M. Histological features of the inter-
face membrane of failed isoelastic cementless prostheses. Int Or-
thop 1990; 14: 399-403. 
[162] Williams DF. Introduction. In: Williams DF, editor. Biocompatibil-
ity of orthopedic implants. Boca Raton, FL: CRC Press; 1985. 
[163] Anderson M, Dhert W, de Bruijn J, et al. Critical size defect in the 
goat`s os ilium. A model to evaluate bone grafts and substitutes. 
Clin Orthop 1999; 364: 231-9. 
[164] Wolff J. Das Gesetz der Transformation der Knochen. Berlin: A. 
Hirschwald; 1882. 
[165] Wolff J. Über die Wechselbeziehungen zwischen der Form und der 
Funktion der einzelnen Gebilde des Organismus. 1st Ed. Leipzig: 
FCW Vogel; 1901. 
[166] Kawcak CE, McIlwraith CW, Norrdin RW, Park RD, James SP. 
The role of subchondral bone in joint disease: a review. Equine Vet 
J 2001; 33(2): 120-6. 
[167] Hughes T, Rady P, Smith E. Potential for the effects of anabolic 
steroid abuse in the immune and neuroendocrine axis. J Neuroim-
munol 1998; 83 (1-2): 162-7. 
[168] Hughes T, Fulep E, Juelich T, Smith E, Stanton G. Modulation of 
immune responses by anabolic androgenic steroids. Int J Immuno-
pharmacol 1995; 17(11): 857-63. 
[169] Angele M, Ayala A, Monfils B, Cioffi W, Bland K, Chaudry I. 
Testosterone and/or low estradiol: normally required but harmful 
immunologically for males after trauma haemorrhage. J Trauma 
1998; 44(1): 78-85. 
[170] Cima L. Polymer substrates for controlled biological interactions. J 
Cell Biochem 1994; 56: 155-61. 
[171] Sarraf P, Sneller M. Pathogenesis of granuloma formation. Expert 
reviews in molecular medicine. [abstract]. 2005; 13.5.2005; 7(8). 
[172] Lepenies J. Helminthen. In: Bühling K, Lepenies J, Witt K. Inten-
sivkurs Pathologie, Allgemeine und spezielle Pathologie. 3rd Ed. 
München: Urban und Fischer; 2001. 
[173] Joachim A. Trichinellose. In: Schnieder T. Veterinärmedizinische 
Parasitologie. 6th Ed. Stuttgart: Parey; 2006. 
 
 
Received: February 28, 2008 Revised: March 13, 2008 Accepted: April 7, 2008 
 
© Nuss and von Rechenberg; Licensee Bentham Open. 
 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/license/by/2.5/), which 
permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited. 
 
 
 
 
 
 
 
 
